Combined impact of first-trimester risk and aspirin adherence on preterm preeclampsia prevention
Aspirin is highly effective for preventing preterm preeclampsia in women at increased risk, but its effect depends on predicted risk and adherence. The absolute benefit of treatment is negligible in low-risk populations. A targeted screen-and-treat strategy using the Fetal Medicine Foundation model maximizes clinical benefit while minimizing unnecessary treatment.
Authors
- S. Cicero
- Kinneret Tenenbaum-Gavish
- Min Yi Tan (ORCID: https://orcid.org/0000-0002-8176-9449)
- Mandeep Singh
- Hamutal Meiri (ORCID: https://orcid.org/0000-0002-2272-5139)
- W. Plasencia (ORCID: https://orcid.org/0000-0003-0182-7678)
- Kate Maclagan (ORCID: https://orcid.org/0000-0003-0686-3053)
- L M Poon
- N. O'Gorman
- Francisca S. Molina (ORCID: https://orcid.org/0000-0001-9190-5654)
- George Papaioannou
- Catalina de Paco Matallana
- Elena Greco
- Daniel L. Rolnik
- Jacques C. Jani
- David Wright
- Nicola Persico
- Deepa Janga
- Kypros H. Nicolaides
- Argyro Syngelaki
Institutions
- Imperial College Healthcare NHS Trust (GB)
- Chinese University of Hong Kong (HK)
- University of Exeter (GB)
- St Mary's Hospital (GB)
- Monash Health (AU)
- King's College Hospital (GB)
- St. Mary's Hospital (GB)
- Monash University (AU)
Publication Details
- Journal
- American Journal of Obstetrics and Gynecology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.ajog.2026.02.014
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00